Cancer of unknown primary (CUP) remains a challenging malignancy with a poor prognosis. Although immune checkpoint inhibitors have shown activity in CUP, available data remains limited. We describe clinical outcomes and a comprehensive biomarker analysis from an expanded access trial of nivolumab in CUP. Patients with...
J. Tanizaki, K. Yonemori, Yuichi Takiguchi et al.· International Journal of Cli...· 0 citations
The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early and locally advanced NSCLC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials.
H. Hayashi, A. Zer, H. Kenmotsu et al.· ESMO Open· 1 citation
Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...
Makoto Nishio, H. Hayashi, Yasushi Goto et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.